Key facts
- This page summarizes James F. Reddoch's Form 4 filing for Royalty Pharma plc (RPRX).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 30 Sep 2022, 16:23.
James F. Reddoch - 28 Sep 2022 Form 4 Insider Report for Royalty Pharma plc (RPRX)
- Reporting relationship
- EVP & Chief Scientific Officer
- Issuer ticker
- RPRX
- Reported as of
- 28 Sep 2022
- Net transaction value
- -$4,122,670
- SEC form
- 4
- Accepted by SEC
- 30 Sep 2022, 16:23:50 UTC
- Prior SEC filing
- 10 Jun 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Sean Weisberg, as Attorney-in-Fact for James F. Reddoch
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
James F. Reddoch filed Form 4 for Royalty Pharma plc (RPRX) on 30 Sep 2022.
Change
- Previous filing in this sequence was filed on 10 Jun 2022.
- Current net transaction value: -$4,122,670.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
RPRX
transaction
Class A Ordinary Shares
Sale
- Transaction value
- $4,122,670
- Shares
- -100,000
- Change %
- -11%
- Price
- $41.23
- Shares after
- 820,800
- Date
- 28 Sep 2022
- Ownership
- By Reddoch RPI LLC
- Footnotes
- F1
RPRX
holding
Class A Ordinary Shares
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 25,030
- Date
- 28 Sep 2022
- Ownership
- By IRA
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
RPRX
transaction
Derivative
LP interests in RPI US Partners 2019, LP
Gift
- Transaction value
- $0
- Shares
- -2,400
- Change %
- -0.5%
- Price
- $0.000000
- Shares after
- 478,870
- Date
- 12 Aug 2022
- Ownership
- By Reddoch RPI LLC
- Underlying class
- Class A Ordinary Shares
- Underlying amount
- 24,000
- Exercise price
- Footnotes
- F2, F3, F4, F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.03 to $41.57 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Footnote F2
No limited partnership interests in RPI US Partners 2019, LP ("RPI US LP") are being exchanged by the Reporting Person. Each limited partnership interest in RPI US LP ("RPI US LP Interest") may be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited ("Holdings"). Each Class B Interest in Holdings so distributed will be exchanged for one Class A Ordinary Share of the Issuer. Any exchanges will be made pursuant to the terms of the Exchange Agreement dated June 16, 2020, among the Issuer, Holdings, RPI US LP, RPI International Holdings 2019, LP, RPI International Partners 2019, LP and RPI EPA Holdings, LP (the "Exchange Agreement"). No additional value will be paid by the Reporting Person in connection with an exchange.
Footnote F3
The Reporting Person made a charitable donation of RPI US LP Interests. No Class A Ordinary Shares or RPI US LP Interests were sold.
Footnote F4
Represents RPI US LP Interests. Each RPI US LP Interest can be exchanged for ten Class B Interests in Holdings at any time and for no additional value, which exchange right does not expire until so converted. Upon such exchange, each Class B Interest in Holdings issued in exchange for a RPI US LP Interest will be exchanged for one Class A Ordinary Share of the Issuer for no additional value.
Footnote F5
The Reporting Person has agreed to retain and not sell 478,870 RPI US LP Interests convertible into 4,788,700 Class A Ordinary Shares before February 2025 pursuant to an agreement by and between the Reporting Person and RP Management, LLC. This restriction is waivable under certain circumstances.